ImmunoTherapyNews.net

Cancer immunotherapy

XagenaNewsletter
Xagena Mappa
Medical Meeting
Farmaexplorer.it

Search results for "Immunotherapy"

Clinical outcome of patients with metastatic prostate cancer ( mPC ) at diagnosis is heterogeneous and unpredictable; thus alternative treatments such as immunotherapy are investigated. Researcher ...


A phase 1/2 clinical trial evaluating dosing, safety, immunogenicity, and overall survival on metastatic colorectal cancer ( mCRC ) patients after immunotherapy with an advanced-generation Ad5 [E1-, E ...


Although tumor infiltrating lymphocyte ( TIL ) density is prognostic and predictive in colorectal cancer ( CRC ), the impact of tumor genetics upon colorectal immunobiology is unclear. Identification ...


Adoptive cell therapy ( ACT ) for cancers using autologous tumor-infiltrating lymphocytes ( TILs ) can induce immune responses and antitumor activity in metastatic melanoma patients. Researchers a ...


Both Ipilimumab, an anti–cytotoxic T-lymphocyte–associated antigen 4 monoclonal antibody ( Yervoy ) and Nivolumab, an anti–programmed death 1 monoclonal antibody ( Opdivo ), have been approved by the ...


The results of the pivotal OPTiM study have shown that Talimogene laherparepvec monotherapy is the first oncolytic immunotherapy to demonstrate therapeutic benefit in a phase 3 trial for patients with ...


Treatment with the immune checkpoint inhibitor Nivolumab ( Opdivo ) has yielded durable responses in some patients with advanced non-small cell lung cancer ( NSCLC ), with a five-year survival rate of ...


The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion, recommending a marketing authorisation of Imfinzi ( Durvalumab ) fo ...


Cancer immunotherapy with checkpoint inhibitors ( CPIs ) is associated with frequent immune-related adverse events ( irAEs ) and is often not recommended for patients with concomitant autoimmune disea ...


A subset of patients treated with immune checkpoint inhibitors experience an accelerated tumor growth rate ( TGR ) in comparison with pretreatment kinetics; this is known as hyperprogression. A stud ...